Hepatitis B core antibody (Anti HBc) is currently considered the most sensitive serological marker for a patient's history of hepatitis B virus (HBV) infection given its long-term persistence in the bloodstream. The serological pattern of isolated Anti HBc (IAHBc) has been of clinical interest over the past several years.,Thegrowing data of IAHBcsuggestingit as a marker for occult HBV infection (OBI). Occult HBV infection defined as HBV DNA detection in serum or the liver by sensitive diagnostic tests in HBsAg negative individuals with or without serologic markers of previous viral exposure. OBI is especially concerned in blood transfusion (BT), organ donation and reactivation of HBV infection following immunosuppressive therapy. HBV reactivation depends on viral and host factors. The important clinical implications of IAHBcis in the setting of co-infection with hepatitis C virus (HCV), reactivation risk of HBV during directly acting anti viral (DAA) therapy in HCV infection which may lead to progression of liver disease and hepatocellular carcinoma (HCC). Antiviral prophylaxis has been recommended in moderate to high risk of reactivation prior to immunosuppressive and biologics. The main goal of therapy is to improve survival and quality of life by preventing disease progression and to prevent consequent development of HCC. It is proposed to perform Anti-HBc test as a screening test prior to blood transfusion, HBVvaccination, DAA and immunosuppressive therapy in addition to HBsAg screening test.
Introduction:
Hepatitis B Virus (HBV) is a major global public health concern. Over 2 billion people worldwide had been infected and 250 million people in world are chronically infectedwith HBV 1 .Regional prevalence of HBV is highest in sub Saharan Africa and South East Asia between 5-10% 1 . Bangladesh belongs to an intermediate prevalent region, which is about 4.2% 2 . Another study conducted atSavar, a suburban area of Bangladeshrevealed prevalence of HBsAg is 5.5% 3 . Hepatitis B core antibody (AntiHBc) is one of the most important serological markers of HBV infection. In HBV endemic area prevalence of Anti HBc is high.In Bangladesh prevalence of AntiHBcamong general population is 31% 2 ,among chronic kidney disease patient is 39.3% 4 . Another study conducted in Kallyanpur, a densely populated community in Dhaka, Bangladesh explored its prevalence is 47.7% among 384 healthy subjects 5 . General populations as well as physicians arevery much worried about Anti HBc positivity.: in special situation likeco infectionofHCV and HBV, immunosuppression, blood transfusion, organ donation.No local guide line exists from any professional . So a local guidancefor management recommendation is needed for proper handling of AntiHBc positive cases.
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Methodology:
We have explored all the online publications available on HVB of Bangladesh from beginning to 2018. We have reviewed the guide lines and recommendations published on HBV and or Anti HBcby professional bodies of Asia Pacific region, European association and United states from 2010 to 2018.Here anti HBc and Anti HBc totalconsidered as clinically synonymous. 11 .In this rare condition Anti HBc will be positive and HBsAg will be negative.
Discussion
Occult HBV infection (OBI)
OBI refers to the presence of HBV DNA in the absence of detectable hepatitis B surface antigen 12 . OBI can be defined by the presence HBV DNA in the serum or liver tissue with either seropositive or seronegativestatus 13 .High risk group for OBI:Blood donors,transplant recipients, patients co-infected with HCV, HIV immunosuppressive therapy or hemodialysis, cryptogenic liver disease, intravenous drug abuser andhealthcare workers 15 .
Types of OBI
Seropositive OBI: Seropositive OBI is characterized by detection of anti HBc with or without Anti HBs antibody with detectable HBV DNA 12 .
Seronegative OBI: Seronegative OBI is described by undetectable both Anti HBc and Anti HBs with detectable HBV DNA 12 .
Most OBI is seropositive butaround 20% of OBI are seronegative representing a population negative for all serum markerof HBV infection but detectable HBV DNA 14 .
Prevalence:OBI varies worldwide.Prevalence rates of OBI are influenced by several factors as follows: (1) geographic differences (endemicity); (2) Co morbid diseases such as chronic hepatitis C; and (3) and the different diagnostic techniques 15 .OBI was reported higher in HBV endemic area, where 41-90% people had previous exposure to HBV 16 .
If IAHBc is confirmed, consideration of subsequent testing should be pursued to evaluate for OBI. Kanget al. 17 
Immunosuppressed conditions
HBV reactivation is a key consideration when initiating immunosuppressive therapy. The 2015 American
Gastroenterological Association guidelines summarized the prevention and treatment of HBV reactivation during immunosuppressive therapy 29 . When considering IAHBc positive patients, the use of antiviral prophylaxis/ preemptive therapy is categorized by level of risk of reactivation, with types of immunosuppression categorized into low,moderateand highrisk groups depending on perceived intensity of therapy and associated risk 12 
HCC risk with IAHBc:
A meta-analysis was conducted on 10 observational studies in 2010 evaluate role of anti-HBc positivity for the risk of HCC in HBsAg-negative subjects with chronic liver disease 30 . Serum antiHBc, an indirect serological marker of occult HBV infection and may be associated with HCC. Study demonstrates that occult HBV patients have a significantly higher risk of HCC than the antiHBs/antiHBc negative. IAHBc was found to have a significantly higher risk of HCC than with antiHBs positive.
Here it may also be hypothesized that circulating antiHBs may prevent the risk of HCC, most probably by controlling HBV replication. Meta-analysis indicates that, at least for HBsAg-negative/antiHBc-positive patients with chronic liver disease, a more accurate monitoring for HCC is hypothesized. This is evident for both Asian and non-Asian populations, in different stages of chronic hepatitis, in HCV etiology, and in patients with or without circulating anti-HBs. The risk of HCC seems to be lower in anti-HBs/anti-HBc-positive patients than in those with "isolated" anti-HBc, 
Guidance:
As per present status of information and evidence to generate guide line is not sufficient for the country. But the following guidance may upgrade the reasoning and decision making in clinical practice.
a. Guidance is required for management of Anti HBc positive person. n. Anti HBc testing may be proposed in addition to HBsAg before vaccination of HBV. HBsAg negative, Anti HBs negative necessitates HBV vaccination. HBsAg negative, Anti HBcpositive and Anti HBs positive does not require vaccination. But in case of HBsAg negative, Anti HBcpositive and Anti HBs negative may not require vaccination.
Conclusion:
Anti HBc positivity is very common in Bangladesh. It includes several spectrums of clinical conditions and related with major issues those have clinical significance. Screening for Anti HBc is mandatory for HBV evaluation, organ transplantation and HCV therapy. Anti HBc is found in different phase of HBV infection, acute, chronic, resolved HBV infection, occult HBV infection.High degree of suspicion of HBV infection with ongoing chronic liver disease in absence HBsAg requires further evaluation. HBV DNA testing and anti viral therapy for HBV is necessary during immunosuppressive therapy. Anti HBc screening should be included for blood transfusion and HBV vaccination.
